{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-007055","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.433950+00:00","generated_at":"2026-06-15T14:27:34.001313+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MAIA Biotechnology reports Q1 2023 net loss $4.1M; positive THIO-101 Phase 2 data and $5.75M offering","bullets":["Cash $7.6M at March 31, 2023; net loss $4.1M for Q1 2023 vs $3.9M for Q1 2022.","R&D expenses $2.2M, G&A expenses $2.0M for the quarter, both modestly higher YoY.","Completed Part A safety lead-in of THIO-101 Phase 2 trial; first two patients alive ~10 and 9 months post treatment.","THIO showed complete and durable responses in hepatocellular carcinoma in vivo models, potentiated with checkpoint inhibitor.","Raised $5.75M gross from public offering of 2,555,500 shares at $2.25 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-007055","json":"https://secwatch.observer/filing/0001564590-23-007055.json","markdown":"https://secwatch.observer/filing/0001564590-23-007055.md","text":"https://secwatch.observer/filing/0001564590-23-007055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023007055/0001564590-23-007055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023007055/maia-8k_20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T14:27:34.001313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f417eac46b3005d2313336db8b48a56ef8fd6b71","claim":"MAIA Biotechnology, Inc. reported first quarter ended March 31, 2023 results: net income approximately $4.1 million.","evidence_excerpt":"Net loss was approximately $4.1 million for the quarter ended March 31, 2023, as compared to net loss of approximately $3.9 million for the quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1878313/000156459023007055/0001564590-23-007055-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"approximately $4.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}